NMD Pharma A/S Revenue and Competitors

Aarhus N, Denmark

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NMD Pharma A/S's estimated annual revenue is currently $10.1M per year.(i)
  • NMD Pharma A/S's estimated revenue per employee is $155,000

Employee Data

  • NMD Pharma A/S has 65 Employees.(i)
  • NMD Pharma A/S grew their employee count by 35% last year.

NMD Pharma A/S's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7910M27846%$204.3MN/A
#2
$42.8M2768%N/AN/A
#3
$3.4M1097-1%$85.7MN/A
#4
$13.2M12-77%$263.3MN/A
#5
$22.9M14817%N/AN/A
#6
$3.6M2310%N/AN/A
#7
$28.5M18437%N/AN/A
#8
$1.6M10-17%N/AN/A
#9
$10.1M6535%N/AN/A
#10
$9.1M5959%N/AN/A
Add Company

What Is NMD Pharma A/S?

Mission\nNMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease.\n\nVision\nA future in which patients with neuromuscular disease live better and more independent lives.\n\nWe have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need.\n\nNMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis.\n\nWe have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases.\n\nFor more information, please visit the company website.

keywords:N/A

N/A

Total Funding

65

Number of Employees

$10.1M

Revenue (est)

35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.5M655%N/A
#2
$16M76-20%N/A
#3
$17.8M818%N/A
#4
$23.7M118-3%N/A
#5
N/A14823%N/A